GSK.L vs. NOVN.SW
GSK.L (GlaxoSmithKline plc) and NOVN.SW (Novartis AG) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, GSK.L returned 6.03%/yr vs 15.47%/yr for NOVN.SW. At a 0.49 correlation, their price movements are largely independent.
Performance
GSK.L vs. NOVN.SW - Performance Comparison
Loading charts...
Different Trading Currencies
GSK.L is traded in GBp, while NOVN.SW is traded in CHF. To make them comparable, the NOVN.SW values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, GSK.L achieves a 10.61% return, which is significantly lower than NOVN.SW's 14.56% return. Over the past 10 years, GSK.L has underperformed NOVN.SW with an annualized return of 6.03%, while NOVN.SW has yielded a comparatively higher 15.47% annualized return.
GSK.L
- 1D
- 1.10%
- 1M
- 6.15%
- YTD
- 10.61%
- 6M
- 10.61%
- 1Y
- 32.87%
- 3Y*
- 17.81%
- 5Y*
- 6.60%
- 10Y*
- 6.03%
NOVN.SW
- 1D
- 0.23%
- 1M
- 3.41%
- YTD
- 14.56%
- 6M
- 18.78%
- 1Y
- 32.48%
- 3Y*
- 24.45%
- 5Y*
- 20.40%
- 10Y*
- 15.47%
GSK.L vs. NOVN.SW - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 10.61% | 41.46% | -3.51% | 4.94% | -25.94% | 26.66% | -20.76% | 25.32% | 19.02% | -10.82% |
NOVN.SW Novartis AG | 14.56% | 36.16% | 2.41% | 33.66% | 19.70% | -2.97% | -0.05% | 26.18% | 11.89% | 10.59% |
Correlation
The correlation between GSK.L and NOVN.SW is 0.62, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.62 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.51 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.48 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.51 |
Correlation (All Time) Calculated using the full available price history since Sep 6, 2007 | 0.49 |
The correlation between GSK.L and NOVN.SW shifts across timeframes, from 0.48 (5 years) to 0.62 (1 year), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GSK.L vs. NOVN.SW — Risk / Return Rank
GSK.L
NOVN.SW
GSK.L vs. NOVN.SW - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK.L) and Novartis AG (NOVN.SW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GSK.L | NOVN.SW | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.39 | ||
| Sortino ratioReturn per unit of downside risk | -0.16 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.30 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 1.78 | 2.54 | -0.75 |
| Martin ratioReturn relative to average drawdown | 4.57 | 6.36 | -1.80 |
Loading charts...
Drawdowns
GSK.L vs. NOVN.SW - Drawdown Comparison
The maximum GSK.L drawdown since its inception was -42.39%, which is greater than NOVN.SW's maximum drawdown of -30.23%. Use the drawdown chart below to compare losses from any high point for GSK.L and NOVN.SW.
Loading charts...
Drawdown Indicators
| GSK.L | NOVN.SW | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -42.39% | -30.23% | -12.16% |
Max Drawdown (1Y)Largest decline over 1 year | -18.35% | -12.98% | -5.37% |
Max Drawdown (3Y)Largest decline over 3 years | -27.42% | -15.76% | -11.66% |
Max Drawdown (5Y)Largest decline over 5 years | -42.39% | -15.76% | -26.63% |
Max Drawdown (10Y)Largest decline over 10 years | -42.39% | -19.79% | -22.60% |
Current DrawdownCurrent decline from peak | -11.02% | -6.47% | -4.55% |
Average DrawdownAverage peak-to-trough decline | -12.78% | -7.01% | -5.77% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.93% | 5.16% | +1.77% |
Volatility
GSK.L vs. NOVN.SW - Volatility Comparison
GlaxoSmithKline plc (GSK.L) and Novartis AG (NOVN.SW) have volatilities of 6.10% and 6.28%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GSK.L | NOVN.SW | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.10% | 6.28% | -0.18% |
Volatility (6M)Calculated over the trailing 6-month period | 18.09% | 14.19% | +3.90% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.04% | 19.45% | +5.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.68% | 19.54% | +4.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.09% | 19.49% | +2.60% |
Dividends
GSK.L vs. NOVN.SW - Dividend Comparison
GSK.L's dividend yield for the trailing twelve months is around 3.38%, more than NOVN.SW's 3.03% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 3.38% | 3.51% | 4.53% | 3.84% | 5.30% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% |
NOVN.SW Novartis AG | 3.03% | 3.19% | 3.72% | 3.77% | 3.71% | 3.74% | 3.53% | 3.10% | 3.77% | 3.78% | 4.12% | 3.39% |
Financials
GSK.L vs. NOVN.SW - Financials Comparison
This section allows you to compare key financial metrics between GlaxoSmithKline plc and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
GSK.L and NOVN.SW have a correlation of 0.62, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for GSK.L and NOVN.SW
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer